Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge
Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.
You may also be interested in...
US FDA Marches Toward Record Novel Approvals With Ionis’ Tegsedi, Leadiant’s Revcovi
Complete response letter for Acacia’s Barhemsys is only rain on Oct. 5 approval parade.
Gardasil Faces Another Safety Study, Looking At Four Rare AEs
Sentinel will consider data from 3m doses of Merck's nine-valent HPV vaccine.
Gardasil Clears Safety Review: No Link To VTE, Mini-Sentinel Study Finds
Study finds no increased risk of venous thromboembolism in more than 650,000 females vaccinated with the HPV vaccine; no labeling changes requested by FDA.